Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas ...
The advertisement aired during the Knicks season opener and featured an altered New York Knicks orange and blue logo that ...
AltaGas Ltd. ("AltaGas" or the "Company") (TSX: ALA) reported third quarter 2025 financial results and provided an update on ...
Companies using AI without proper oversight are exposing themselves to unnecessary risk, according to cybersecurity analysts.
Our proprietary forecasting models and team of meteorologists provide detailed forecasts for thousands of breaks around the globe. Go Premium and we’ll help you know before you go.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback